The WHO 2016 guidelines for classification of tumours of the central nervous system integrates molecular genomic information with histological analysis. The central nervous system tumour service offers a range of tests for the differential diagnosis of CNS tumours, provides prognostic information, and may aid in treatment decisions or clinical trial recruitment.
Please refer to the National Genomic Test Directory for Cancer here.
MGMT promoter hypermethylation 14 calendar days
p19q co-deletion 14 calendar days
BRAF codon 600 mutations 14 calendar days
KIAA1549:BRAF fusion 14 calendar days
C11orf95-RELA fusion 14 calendar days
EGFRvIII Transcript 14 calendar days
Meningioma/schwannoma panel 14 calendar days
CNS panel 14 calendar days
Please refer to our Sample Requirements section before sending any samples to us for testing.
- Referrals will be accepted from oncologists and pathologists. If MGMT hypermethylation or KIAA1549-BRAF fusion testing is requested in addition to another test, we require an additional 4×5µM sections.